Screening and Early Detection of Gastric Cancer: East Versus West

Surgical Clinics of North America

Volumn 95, Issue 5, 2015, Pages 1053-1066

  Suh, Yun Suhk ^a   Yang, Han Kwang ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

Gastric cancer; Regional disparity; Screening; Treatment

Indexed keywords

ASIAN; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; DIET; EARLY DIAGNOSIS; GASTRECTOMY; GENETIC DIFFERENCE; HELICOBACTER PYLORI; HUMAN; JAPAN; KOREA; LIFE EXPECTANCY; LYMPH NODE DISSECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SMOKING; STOMACH CANCER; TAIWAN; CULTURAL ANTHROPOLOGY; GENETIC PREDISPOSITION; INCIDENCE; PROCEDURES; PROGNOSIS; SOUTH KOREA; STOMACH NEOPLASMS;

EARLY DETECTION OF CANCER; GASTRECTOMY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; JAPAN; LYMPH NODE EXCISION; PROGNOSIS; REPUBLIC OF KOREA; RISK FACTORS; STOMACH NEOPLASMS; TAIWAN; WESTERN WORLD;

EID: 84940614790     PISSN: 00396109     EISSN: 15583171     Source Type: Journal    
DOI: 10.1016/j.suc.2015.05.012     Document Type: Review

References (87)

1. Ferlay J., Soerjomataram I., Dikshit R., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015, 136(5):E359-E386.
2. Department of Economic and Social Affairs of the United Nations Secretariat World population prospects: the 2012 revision 2013, Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat, New York.
3. Parsonnet J., Friedman G.D., Vandersteen D.P., et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991, 325(16):1127-1131.
4. Uemura N., Okamoto S., Yamamoto S., et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001, 345(11):784-789.
5. Fock K.M., Talley N., Moayyedi P., et al. Asia-Pacific consensus guidelines on gastric cancer prevention. J Gastroenterol Hepatol 2008, 23(3):351-365.
6. Kamangar F., Dawsey S.M., Blaser M.J., et al. Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity. J Natl Cancer Inst 2006, 98(20):1445-1452.
7. Ogura K., Hirata Y., Yanai A., et al. The effect of Helicobacter pylori eradication on reducing the incidence of gastric cancer. J Clin Gastroenterol 2008, 42(3):279-283.
8. Wong B.C.-Y., Lam S.K., Wong W.M., et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004, 291(2):187-194.
9. You W.-C., Brown L.M., Zhang L., et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst 2006, 98(14):974-983.
10. Fukase K., Kato M., Kikuchi S., et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008, 372(9636):392-397.
11. Wu C.Y., Kuo K.N., Wu M.S., et al. Early Helicobacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease. Gastroenterology 2009, 137(5):1641-1648.e1-2.
12. Fuccio L., Zagari R.M., Eusebi L.H., et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer?. Ann Intern Med 2009, 151(2):121-128.
13. Herrero R., Parsonnet J., Greenberg E.R. Prevention of gastric cancer. JAMA 2014, 312(12):1197-1198.
14. Tatematsu M., Takahashi M., Fukushima S., et al. Effects in rats of sodium chloride on experimental gastric cancers induced by N-methyl-N-nitro-N-nitrosoguanidine or 4-nitroquinoline-1-oxide. J Natl Cancer Inst 1975, 55(1):101-106.
15. Furihata C., Ohta H., Katsuyama T. Cause and effect between concentration-dependent tissue damage and temporary cell proliferation in rat stomach mucosa by NaCl, a stomach tumor promoter. Carcinogenesis 1996, 17(3):401-406.
16. Shikata K., Kiyohara Y., Kubo M., et al. A prospective study of dietary salt intake and gastric cancer incidence in a defined Japanese population: the Hisayama study. Int J Cancer 2006, 119(1):196-201.
17. Lee S.-A., Kang D., Shim K., et al. Original article effect of diet and Helicobacter pylori infection to the risk of early gastric cancer. J Epidemiol 2003, 13(3):162-168.
18. Joossens J.V., Hill M., Elliott P., et al. Dietary salt, nitrate and stomach cancer mortality in 24 countries. Int J Epidemiol 1996, 25(3):494-504.
19. Nishino Y., Inoue M., Tsuji I., et al. Tobacco smoking and gastric cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population. Jpn J Clin Oncol 2006, 36(12):800-807.
20. Ladeiras-Lopes R., Pereira A.K., Nogueira A., et al. Smoking and gastric cancer: systematic review and meta-analysis of cohort studies. Cancer Causes Control 2008, 19(7):689-701.
21. La Torre G., Chiaradia G., Gianfagna F., et al. Smoking status and gastric cancer risk: an updated meta-analysis of case-control studies published in the past ten years. Tumori 2009, 95(1):13.
22. Shikata K., Doi Y., Yonemoto K., et al. Population-based prospective study of the combined influence of cigarette smoking and Helicobacter pylori infection on gastric cancer incidence. The Hisayama Study. Am J Epidemiol 2008, 168(12):1409-1415.
23. Information Committee of the Korean Gastric Cancer Association 2004 Nationwide gastric cancer report in Korea. J Korean Gastric Cancer Assoc 2007, 7:47-54.
24. Jeong O., Park Y.-K. Clinicopathological features and surgical treatment of gastric cancer in South Korea: the results of 2009 nationwide survey on surgically treated gastric cancer patients. J Gastric Cancer 2011, 11(2):69-77.
25. Ahn H., Lee H.J., Yoo M.W., et al. Changes in clinicopathological features and survival after gastrectomy for gastric cancer over a 20-year period. Br J Surg 2011, 98(2):255-260.
26. Kim Y.G., Kong S.-H., Oh S.-Y., et al. Effects of screening on gastric cancer management: comparative analysis of the results in 2006 and in 2011. J Gastric Cancer 2014, 14(2):129-134.
27. Nam S.Y., Choi I.J., Park K.W., et al. Effect of repeated endoscopic screening on the incidence and treatment of gastric cancer in health screenees. Eur J Gastroenterol Hepatol 2009, 21(8):855-860.
28. Chung S.J., Park M.J., Kang S.J., et al. Effect of annual endoscopic screening on clinicopathologic characteristics and treatment modality of gastric cancer in a high-incidence region of Korea. Int J Cancer 2012, 131(10):2376-2384.
29. Hamashima C., Shibuya D., Yamazaki H., et al. The Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol 2008, 38(4):259-267.
30. Inaba S., Hirayama H., Nagata C., et al. Evaluation of a screening program on reduction of gastric cancer mortality in Japan: preliminary results from a cohort study. Prev Med 1999, 29(2):102-106.
31. Mizoue T., Yoshimura T., Tokui N., et al. Prospective study of screening for stomach cancer in Japan. Int J Cancer 2003, 106(1):103-107.
32. Lee K.J., Inoue M., Otani T., et al. Gastric cancer screening and subsequent risk of gastric cancer: a large-scale population-based cohort study, with a 13-year follow-up in Japan. Int J Cancer 2006, 118(9):2315-2321.
33. Miyamoto A., Kuriyama S., Nishino Y., et al. Lower risk of death from gastric cancer among participants of gastric cancer screening in Japan: a population-based cohort study. Prev Med 2007, 44(1):12-19.
34. Fukao A., Tsubono Y., Tsuji I., et al. The evaluation of screening for gastric cancer in Miyagi Prefecture, Japan: a population-based case-control study. Int J Cancer 1995, 60(1):45-48.
35. Yatake H., Takeda Y., Katsuda T., et al. Improved detection of gastric cancer during screening by additional radiographs as judged necessary by the radiographer. Jpn J Radiol 2011, 29(3):177-186.
36. Kitahara F., Kobayashi K., Sato T., et al. Accuracy of screening for gastric cancer using serum pepsinogen concentrations. Gut 1999, 44(5):693-697.
37. Miki K., Morita M., Sasajima M., et al. Usefulness of gastric cancer screening using the serum pepsinogen test method. Am J Gastroenterol 2003, 98(4):735-739.
38. Asaka M., Kato M., Graham D.Y. Strategy for eliminating gastric cancer in Japan. Helicobacter 2010, 15(6):486-490.
39. Miki K., Fujishiro M., Kodashima S., et al. Long-term results of gastric cancer screening using the serum pepsinogen test method among an asymptomatic middle-aged Japanese population. Dig Endosc 2009, 21(2):78-81.
40. Ang T.L., Fock K.M., Dhamodaran S., et al. Racial differences in Helicobacter pylori, serum pepsinogen and gastric cancer incidence in an urban Asian population. J Gastroenterol Hepatol 2005, 20(10):1603-1609.
41. Kang J.M., Kim N., Yoo J.Y., et al. The role of serum pepsinogen and gastrin test for the detection of gastric cancer in Korea. Helicobacter 2008, 13(2):146-156.
42. Kim N., Jung H.C. The role of serum pepsinogen in the detection of gastric cancer. Gut and liver 2010, 4(3):307-319.
43. Liu C.-Y., Wu C.-Y., Lin J.-T., et al. Multistate and multifactorial progression of gastric cancer: results from community-based mass screening for gastric cancer. J Med Screen 2006, 13(suppl 1):2-5.
44. Lee Y.-C., Chen T.H.-H., Chiu H.-M., et al. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut 2013, 62(5):676-682.
45. Christie J., Shepherd N., Codling B., et al. Gastric cancer below the age of 55: implications for screening patients with uncomplicated dyspepsia. Gut 1997, 41(4):513-517.
46. Roderick P., Davies R., Raftery J., et al. The cost-effectiveness of screening for Helicobacter pylori to reduce mortality and morbidity from gastric cancer and peptic ulcer disease: a discrete-event simulation model. Health Technol Assess 2003, 7(6):1-86.
47. Logan R., Langman M. Screening for gastric cancer after gastric surgery. Lancet 1983, 322(8351):667-670.
48. Akoh J., Macintyre I. Improving survival in gastric cancer: review of 5-year survival rates in English language publications from 1970. Br J Surg 1992, 79(4):293-299.
49. Cunningham S.C., Kamangar F., Kim M.P., et al. Survival after gastric adenocarcinoma resection: eighteen-year experience at a single institution. J Gastrointest Surg 2005, 9(5):718-725.
50. Leung W.K., Wu M.-S., Kakugawa Y., et al. Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol 2008, 9(3):279-287.
51. Suvakovic Z., Bramble M., Jones R., et al. Improving the detection rate of early gastric cancer requires more than open access gastroscopy: a five year study. Gut 1997, 41(3):308-313.
52. National Cancer Institute. A snapshot of stomach cancer. Available at: Accessed February 7, 2015. http://www.cancer.gov/researchandfunding/snapshots/stomach.
53. Cho E., Kang M.H., Choi K.S., et al. Cost-effectiveness outcomes of the national gastric cancer screening program in South Korea. Asian Pac J Cancer Prev 2013, 14(4):2533-2540.
54. Dan Y.Y., So J., Yeoh K.G. Endoscopic screening for gastric cancer. Clin Gastroenterol Hepatol 2006, 4(6):709-716.
55. Lee Y.-C., Lin J.-T., Wu H.-M., et al. Cost-effectiveness analysis between primary and secondary preventive strategies for gastric cancer. Cancer Epidemiol Biomarkers Prev 2007, 16(5):875-885.
56. Taylor V.M., Ko L.K., Hwang J.H., et al. Gastric cancer in Asian American populations: a neglected health disparity. Asian Pac J Cancer Prev 2014, 15(24):10565-10571.
57. Imperiale T.F., Ransohoff D.F., Itzkowitz S.H., et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 2014, 370(14):1287-1297.
58. Japanese Gastric Cancer Association Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer 2011, 14(2):113-123.
59. Wang J., Dang P., Raut C.P., et al. Comparison of a lymph node ratio-based staging system with the 7th AJCC system for gastric cancer: analysis of 18,043 patients from the SEER database. Ann Surg 2012, 255(3):478-485.
60. Cuschieri A., Joypaul V., Fayers P., et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. Lancet 1996, 347(9007):995-999.
61. Cuschieri A., Weeden S., Fielding J., et al. Patient survival after D 1 and D 2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Br J Cancer 1999, 79(9/10):1522.
62. Bonenkamp J., Hermans J., Sasako M., et al. Extended lymph-node dissection for gastric cancer. N Engl J Med 1999, 340(12):908-914.
63. Degiuli M., Sasako M., Ponti A., et al. Survival results of a multicentre phase II study to evaluate D2 gastrectomy for gastric cancer. Br J Cancer 2004, 90(9):1727-1732.
64. Degiuli M., Sasako M., Ponti A., et al. Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer. Br J Surg 2014, 101(2):23-31.
65. Markar S.R., Karthikesalingam A., Jackson D., et al. Long-term survival after gastrectomy for cancer in randomized, controlled oncological trials: comparison between West and East. Ann Surg Oncol 2013, 20(7):2328-2338.
66. Songun I., Putter H., Kranenbarg E.M.-K., et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010, 11(5):439-449.
67. Cuschieri A., Hanna G.B. Meta-analysis of d1 versus d2 gastrectomy for gastric adenocarcinoma: let us move on to another era. Ann Surg 2014, 259(6):e90.
68. Schmidt B., Chang K.K., Maduekwe U.N., et al. D2 lymphadenectomy with surgical ex vivo dissection into node stations for gastric adenocarcinoma can be performed safely in Western patients and ensures optimal staging. Ann Surg Oncol 2013, 20(9):2991-2999.
69. Ahn H., Lee H., Hahn S., et al. Evaluation of the Seventh American Joint Committee on Cancer/International Union Against Cancer Classification of gastric adenocarcinoma in comparison with the sixth classification. Cancer 2010, 116(24):5592-5598.
70. Lee S.-W., Nomura E., Bouras G., et al. Long-term oncologic outcomes from laparoscopic gastrectomy for gastric cancer: a single-center experience of 601 consecutive resections. J Am Coll Surg 2010, 211(1):33-40.
71. Qiu M.-Z., Wang Z.-Q., Zhang D.-S., et al. Comparison of 6th and 7th AJCC TNM staging classification for carcinoma of the stomach in China. Ann Surg Oncol 2011, 18(7):1869-1876.
72. Strong V.E., Song K.Y., Park C.H., et al. Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. Ann Surg 2010, 251(4):640-646.
73. Nomura A., Stemmermann G.N., Chyou P.H., et al. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med 1991, 325(16):1132.
74. Yao J.C., Tseng J.F., Worah S., et al. Clinicopathologic behavior of gastric adenocarcinoma in Hispanic patients: analysis of a single institution's experience over 15 years. J Clin Oncol 2005, 23(13):3094.
75. An C., Choi I.S., Yao J.C., et al. Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. Clin Cancer Res 2005, 11(2):656.
76. Steinberg M.L., Hwang B.J., Tang L., et al. E-cadherin gene alterations in gastric cancers in different ethnic populations. Ethn Dis 2008, 18(2 Suppl 2). S2-70-S2-74.
77. Shah M.A., Khanin R., Tang L., et al. Molecular classification of gastric cancer: a new paradigm. Clin Cancer Res 2011, 17(9):2693-2701.
78. Tan I.B., Ivanova T., Lim K.H., et al. Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology 2011, 141(2):476-485.e11.
79. Wang K., Kan J., Yuen S.T., et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet 2011, 43(12):1219-1223.
80. Deng N., Goh L.K., Wang H., et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 2012, 61:673-684.
81. Wang G., Hu N., Yang H.H., et al. Comparison of global gene expression of gastric cardia and noncardia cancers from a high-risk population in china. PLoS One 2013, 8(5):e63826.
82. Network Genome Atlas Research Network Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014, 513(7517):202-209.
83. Yoon K.-A., Ku J.-L., Yang H.-K., et al. Germline mutations of E-cadherin gene in Korean familial gastric cancer patients. J Hum Genet 1999, 44(3):177-180.
84. Shinmura K., Kohno T., Takahashi M., et al. Familial gastric cancer: clinicopathological characteristics, RER phenotype and germline p53 and E-cadherin mutations. Carcinogenesis 1999, 20(6):1127-1131.
85. Yabuta T., Shinmura K., Tani M., et al. E-cadherin gene variants in gastric cancer families whose probands are diagnosed with diffuse gastric cancer. Int J Cancer 2002, 101(5):434-441.
86. Blair V., Martin I., Shaw D., et al. Hereditary diffuse gastric cancer: diagnosis and management. Clin Gastroenterol Hepatol 2006, 4(3):262-275.
87. Fitzgerald R.C., Hardwick R., Huntsman D., et al. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet 2010, 47(7):436-444.